View in EDS

Visfatin, a New Adipocytokine, Is Predominantly Related to Inflammation/Endothelial Damage in Kidney Allograft Recipients

Saved in:
Bibliographic Details
Title: Visfatin, a New Adipocytokine, Is Predominantly Related to Inflammation/Endothelial Damage in Kidney Allograft Recipients
Authors: E Koc-Zorawska, Michal Mysliwiec, Jacek S. Malyszko
Source: Transplantation Proceedings. 41:150-153
Publisher Information: Elsevier BV, 2008.
Publication Year: 2008
Subject Terms: Adult, Male, 0301 basic medicine, Kidney transplantation - pathology, Biomarkers - blood, Reference values, 03 medical and health sciences, 0302 clinical medicine, Reference Values, vascular - pathology, Diabetic nephropathies - enzymology, Humans, Transplantation, Homologous, Cytokines - metabolism, Diabetic Nephropathies, Endothelium, Inflammation - enzymology, Inflammation - pathology, Middle aged, Nicotinamide phosphoribosyltransferase - metabolism, Nicotinamide Phosphoribosyltransferase, Blood Coagulation, Aged, Inflammation, Transplantation, vascular - enzymology, Fibrinolysis, Kidney transplantation - immunology, Blood coagulation, Middle Aged, Kidney Transplantation, Diabetic nephropathies - surgery, 3. Good health, homologous, Cytokines, Female, Endothelium, Vascular, Biomarkers, Immunosuppressive Agents, Immunosuppressive agents - therapeutic use
Description: Visfatin, a ubiquitous adipokine, was first described in 2005. It was found to be selectively up-regulated in the adipose tissue and to have insulin-mimetic effects. It has been reported that visfatin is associated with endothelial damage in chronic kidney disease. We investigated plasma visfatin levels (using commercially available kits) in 100 clinically stable kidney allograft recipients. We assessed visfatin markers of coagulation: thrombin-antithrombin complexes, prothrombin fragments 1 + 2; fibrinolysis: tissue plasminogen activator, plasminogen activator inhibitor, plasmin-antiplasmin complexes; endothelial function/injury: von Willebrand factor, thrombomodulin, intracellular adhesion molecule, vascular cell adhesion molecule (VCAM); inflammation: hsCRP and interleukin-6. Visfatin was significantly higher in kidney allograft recipients than in healthy volunteers. Visfatin did not differ significantly between diabetic and nondiabetics, hypertensives and normotensives, patients with and without coronary artery disease, and between male and female subjects. Type of immunosuppressive regimen (mycophenolate mofetil vs azathioprine) did not affect visfatin levels. On univariate analysis, visfatin correlated positively with prothrombin fragments 1 + 2, VCAM, creatinine, high-sensitivity C-reactive protein, and negatively with albumin. In multivariate analysis, only VCAM was associated with visfatin in kidney allograft recipients. Visfatin, which is related to markers of inflammation, may represent a novel link between inflammation and adipocytokines among long-term kidney transplant recipients.
Document Type: Article
Other literature type
Language: English
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2008.10.086
DOI: 10.1097/01.tp.0000331700.75696.61
Access URL: https://pubmed.ncbi.nlm.nih.gov/19249500
https://www.ncbi.nlm.nih.gov/pubmed/19249500
https://europepmc.org/article/MED/19249500
https://www.sciencedirect.com/science/article/pii/S004113450801614X
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00007890-200807271-01061
Rights: Elsevier TDM
Accession Number: edsair.doi.dedup.....f1daeae58f284c6d65e512883032f9ba
Database: OpenAIRE
Description
Abstract:Visfatin, a ubiquitous adipokine, was first described in 2005. It was found to be selectively up-regulated in the adipose tissue and to have insulin-mimetic effects. It has been reported that visfatin is associated with endothelial damage in chronic kidney disease. We investigated plasma visfatin levels (using commercially available kits) in 100 clinically stable kidney allograft recipients. We assessed visfatin markers of coagulation: thrombin-antithrombin complexes, prothrombin fragments 1 + 2; fibrinolysis: tissue plasminogen activator, plasminogen activator inhibitor, plasmin-antiplasmin complexes; endothelial function/injury: von Willebrand factor, thrombomodulin, intracellular adhesion molecule, vascular cell adhesion molecule (VCAM); inflammation: hsCRP and interleukin-6. Visfatin was significantly higher in kidney allograft recipients than in healthy volunteers. Visfatin did not differ significantly between diabetic and nondiabetics, hypertensives and normotensives, patients with and without coronary artery disease, and between male and female subjects. Type of immunosuppressive regimen (mycophenolate mofetil vs azathioprine) did not affect visfatin levels. On univariate analysis, visfatin correlated positively with prothrombin fragments 1 + 2, VCAM, creatinine, high-sensitivity C-reactive protein, and negatively with albumin. In multivariate analysis, only VCAM was associated with visfatin in kidney allograft recipients. Visfatin, which is related to markers of inflammation, may represent a novel link between inflammation and adipocytokines among long-term kidney transplant recipients.
ISSN:00411345
DOI:10.1016/j.transproceed.2008.10.086